Navigation Links
Further support for use of statins in Alzheimer’s disease,

People who take the cholesterol-lowering drugs called statins may reduce their risk of developing Alzheimer's disease by nearly 80%. Statins have been proved to offer// powerful protection against heart disease for people with high blood cholesterol. The findings provide the strongest evidence to date that statin drugs may also help protect people from Alzheimer's disease.

An earlier, smaller study had suggested these drugs might offer some protection against Alzheimer's disease. Green and his colleagues decided to do a large study that included 988 people with Alzheimer's disease and 1,669 healthy family members, who acted as controls. The researchers took into account age and other factors that put people at risk and still found that the statins offered a mighty shield against the Alzheimer’s disease.

Researchers speculate that statins may reduce the brain's production of beta-amyloid, a protein thought to cause Alzheimer's disease. But there's also a possibility that statins might help slow the memory loss and other symptoms in people who already have the disease. Studies to test that theory are under way
'"/>




Page: 1

Related medicine news :

1. Clinical Impact of Activity and Abdominal Pressure on Pelvic Floor Dysfunction Need to Be Further Analyzed
2. Doctor Accused Of Misdiagnosing 208 Patients: Further Investigation Ordered
3. NHS Recommends Further Cost Cutting Measures
4. Medha Patkars Condition Deteriorates Further
5. Oxford Radcliffe Hospitals Warns Of Further Job Losses
6. Further Studies Needed To Completely Understand About Ventricular Fibrillation
7. Further improvements envisaged at Carstairs
8. Further Studies on AIDS Prevention Gels Stopped
9. UCLA Find Yields Further Insight into Causes of Parkinson’s Diseas
10. Salt Consumption Needs To Drop Further
11. Prince Charles lends support to Alternative Medicine
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... Olathe, KS (PRWEB) , ... April 28, 2017 ... ... system have typically been previously exposed to more adverse experiences than children in ... have experienced trauma such as abuse, neglect or other family challenges. While no ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early ... substantially improve drug safety and minimize the cost of development. In this webinar, ... inhibition using cell lines and for cardiac toxicity using induced pluripotent stem cells ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... the Creator responds to and which He does not. Yisrayl says with so many ... is the true name, but he says with a little Scripture, backed with a lot ...
(Date:4/28/2017)... ... 2017 , ... Intellitec Solutions announced the publication of a ... Dynamics GP solution that integrates to their PointClickCare EHR software package. With the ... Brooke Grove now has the capability to achieve its goal for a comprehensive ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor that ... his presence to an educational purpose as the host of the “Informed” series. The ... In a recent episode, the series focuses on thyroid cancer. , Although thyroid cancer ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and Markets ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ... offering. ... drug delivery technologies will rise from USD 20 Billion in 2015 ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
Breaking Medicine Technology: